Shots:

• Clovis Oncology’s Rubraca (rucaparib) enters in EU with its first launch in Germany and is approved for both treatment and maintenance treatment of ovarian cancer in women
• The launch is based on P-III ARIEL3 study assessing Rubraca (rucaparib) vs PBO in 564 women with relapsed epithelial ovarian- fallopian tube or primary peritoneal cancer in response to platinum-based chemotherapy in ratio 2:1
• Rubraca (600mg- q2d-) is an oral PARP inhibitor used as monothx & as combination for multiple tumors with its expected launch in other EU countries in H2’19 & 2020

Ref: Clovis Oncology | Image: Condit